Triastek, Inc. (Triastek), a global leader in 3D printed pharmaceuticals, has 
completed its Series B financing, raising US$ 50 million (RMB 330 million). 
This round of investment was co-led by Matrix Partners China and CPE, with 
participation from Shanghai Sci-Tech Innovation Center Capital (SSICC) and 
existing investors, Morningside Ventures, Dalton Venture and Yunqi Partners. In 
addition to supporting the ongoing development of the first IND-approved 
product in clinical trials, the proceeds will also be used to expand the 3D 
printed drug product pipeline and advancing Triastek's vision of creating a new 
era of global intelligent pharmaceutical manufacturing.

Triastek co-founder and CEO Dr. Senping Cheng said, "We appreciate the support 
from Matrix Partners China, CPE, SSICC and our existing shareholders. It is 
Triastek's unrelenting goal to develop cutting-edge therapeutics that address 
unmet patient needs, revolutionize pharmaceutical manufacturing and improve 
human health. We will leverage the advantages of 3D printing of pharmaceuticals 
as a digital manufacturing technology and incorporate emerging technologies 
such as artificial intelligence to lead off a new era in advanced, intelligent 
pharmaceutical manufacturing."

Matrix Partners China partner Dr. Eric Yu added, "Triastek's breakthrough 3D 
printing pharmaceutical technology platform can create almost all types of 
target drug release profiles. We are optimistic that in the future, through its 
technology platform, Triastek will continue to bring forth innovative drugs for 
patients with unmet clinical needs. "

CPE executive director Jing Wu commented, "We have always been focused on 
emerging technologies in the field of pharmaceutical development. We firmly 
believe that Triastek's 3D printing pharmaceutical technology will be a 
platform with global influence and become a development and manufacturing 
leader for the whole industry. Triastek's contributions will accelerate the 
realization of digitization and intelligent manufacturing across the 
pharmaceutical industry."

SSICC executive vice president Dr. Zhide Yuan said, "Triastek has 
multidisciplinary teams in pharmaceutical sciences, mechanical engineering, 
material sciences, etc.,rich experience in pharmaceutical manufacturing and 
strong interdisciplinary execution ability. We are optimistic about the 
company's technology and team capabilities and look forward to more extensive 
application of the company's technology in drug R & D and production."

Founded in 2015 as the first 3D printing pharmaceutical company in China, 
Triastek is committed to building a novel 3D printing pharmaceutical technology 
platform with its comprehensive proprietary technologies encompassing dosage 
form design, digital pharmaceutical product development, and intelligent 
manufacturing. With its proprietary Melt Extrusion Deposition (MED(R)) 3D 
printing technology, the company is the first Chinese pharmaceutical company to 
be accepted into the US FDA's Emerging Technology Program. Triastek's 
technology provides customized solutions for most oral solid dosage forms. 
Compared to the traditional iterative drug development process and tablet 
compression methods, MED 3D printing provides a paradigm shift in 
pharmaceutical product development and manufacturing. The versatility of the 
tablet structure resulting from 3D printing technology permits precise and 
programmed control of the drug release profile, thereby optimizing the PK 
profile of new and existing drug products.

Using MED 3D printing technology, Triastek has built a product pipeline 
including new formulations and new combination product candidates intended to 
meet specific clinical needs and thereby improve drug therapy outcomes. In 
January 2021, the company received IND approval from the US FDA for its first 
product T19, being developed for the treatment of rheumatoid arthritis. The 
company's second product T20 received positive pre-IND feedback from the US FDA 
in March 2021 and an IND application submission for T20 is planned for the end 
of this year.

In addition to the development of in-house products, Triastek is collaborating 
with leading multinational and Chinese pharmaceutical companies to explore a 
variety of application scenarios for the MED 3D printing technology, such as 
developing formulations to provide solution for the poor water soluble new 
chemical entities as well as extending the lifecycle of approved/developed 
products. Through these collaborations, Triastek provides a significant value 
proposition for partner companies through the development of novel, unique and 
competitive pharmaceutical products in combating the challenges of 
developability of new compound and fine-tuning PK profile in early product 
development to shorten the time for human study.

For more information, please check: https://www.triastek.com

Source: Triastek, Inc.